4 years ago

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation

Yutaka Yonezawa, Rie Sugawara, Toshihiko Ishimitsu, Shigeo Horinaka
Aims The aim of the present study was to demonstrate evidence of reduced thrombin generation at the trough plasma rivaroxaban concentration. Methods A single-centre, prospective, non-randomised, drug intervention, self-controlled study was conducted in 51 anticoagulation therapy-naïve patients with non-valvular atrial fibrillation. Plasma rivaroxaban concentration was measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and anti-factor Xa chromogenic assay. Partial thrombin time (PT), protein-C activity and protein-S antigen, prothrombin fragment 1+2 (F1+2), D-dimer, thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasminogen activator inhibitor-1 (PAI-1) and tissue factor pathway inhibitor (TFPI) were also measured at the trough steady state after 4 weeks of rivaroxaban treatment and compared with baseline. Results Plasma concentrations obtained by LC-MS/MS and anti-Xa assay were correlated (r = 0.841, P < 0.001). The mean concentration of rivaroxaban at the trough steady state was 23.6 ng/ml, at which F1+2, TAT and D-dimer had decreased from the baseline values (P < 0.0001, P = 0.029 and P < 0.005, respectively). PT was prolonged (+0.59 seconds, P < 0.0001). TFPI increased from baseline to the trough steady state in the first to third quartile groups (+0.79 pg/ml, P = 0.048). In contrast, PAI-1, protein-C activity, protein-S antigen and TM remained within the normal range at the trough steady state. Conclusions Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with non-valvular atrial fibrillation.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bcp.13429

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.